Literature DB >> 10549646

Functional visual loss in amblyopia and the effect of occlusion therapy.

A J Simmers1, L S Gray, P V McGraw, B Winn.   

Abstract

PURPOSE: The aim of this study was to define the nature of functional visual loss in amblyopia and to identify those subjects whose amblyopia is chiefly due to one or more of the following deficits: abnormal contour interaction, abnormal eye movements, abnormal contrast perception, or positional uncertainty.
METHODS: Fifty amblyopic children with a mean age of 5.6+/-1.3 years were referred from diverse sources. In addition to routine orthoptic and optometric evaluation the principal visual deficits in the amblyopic eye of each subject were identified using the following measures of visual acuity: high contrast linear, single optotype, repeat letter and low contrast linear, plus Vernier and displacement thresholds. These measures were repeated as the children underwent a prescribed occlusion therapy regime, after parental consent.
RESULTS: All amblyopic subjects demonstrated a functional loss in each of the tests used, and occlusion therapy appeared to improve all aspects of the amblyopia. High contrast visual acuity was not always the primary deficit in visual function, and when amblyopic subjects were divided according to their primary visual loss, this visual function was found to show the greatest improvement with treatment.
CONCLUSIONS: These results suggest that to successfully identify the primary visual deficit and monitor the success of occlusion therapy it is necessary to assess other aspects of visual function in amblyopia.

Entities:  

Mesh:

Year:  1999        PMID: 10549646

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Evaluating reading acuity and speed in children with microstrabismic amblyopia using a standardized reading chart system.

Authors:  E Stifter; G Burggasser; E Hirmann; A Thaler; W Radner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-08       Impact factor: 3.117

Review 2.  Improving the performance of the amblyopic visual system.

Authors:  Dennis M Levi; Roger W Li
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-02-12       Impact factor: 6.237

Review 3.  Can perceptual learning be used to treat amblyopia beyond the critical period of visual development?

Authors:  Andrew T Astle; Ben S Webb; Paul V McGraw
Journal:  Ophthalmic Physiol Opt       Date:  2011-11       Impact factor: 3.117

4.  Monocular and binocular reading performance in children with microstrabismic amblyopia.

Authors:  E Stifter; G Burggasser; E Hirmann; A Thaler; W Radner
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

Review 5.  Amblyopia: a mini review of the literature.

Authors:  Evgenia Kanonidou
Journal:  Int Ophthalmol       Date:  2011-03-20       Impact factor: 2.031

6.  Can human amblyopia be treated in adulthood?

Authors:  Andrew T Astle; Paul V McGraw; Ben S Webb
Journal:  Strabismus       Date:  2011-09

7.  Age- and stereovision-dependent eye-hand coordination deficits in children with amblyopia and abnormal binocularity.

Authors:  Simon Grant; Catherine Suttle; Dean R Melmoth; Miriam L Conway; John J Sloper
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-05       Impact factor: 4.799

8.  Deficits of spatial localization in children with strabismic amblyopia.

Authors:  Maria Fronius; Ruxandra Sireteanu; Alina Zubcov
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-06-09       Impact factor: 3.117

9.  Beyond screening for risk factors: objective detection of strabismus and amblyopia.

Authors:  Reed M Jost; Susan E Yanni; Cynthia L Beauchamp; David R Stager; David Stager; Lori Dao; Eileen E Birch
Journal:  JAMA Ophthalmol       Date:  2014-07       Impact factor: 7.389

10.  Crowded letter and crowded picture logMAR acuity in children with amblyopia: a quantitative comparison.

Authors:  Cathy O'Boyle; Sean I Chen; Julie-Anne Little
Journal:  Br J Ophthalmol       Date:  2016-07-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.